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Erdheim-Chester disease (ECD) is a rare, non-Langerhans histocytosis, mainly 
affecting adults ages 40 - 70. This clonal disorder is marked by recurrent 
BRAFV600E mutations in over 68% of patients and presents as uncontrolled 
inflammation of multiple organ systems. This pattern of cytokine expression and protein kinase 
signaling results in pro-inflammatory recruitment of histiocytes. Only 500 cases have been described 
in the literature with longstanding uncertainty about etiology and classification. While data supporting 
treatment is limited, IFN-α and pegylated IFN-α are considered first-line options with Kinase inhibitors 
demonstrating dramatic improvement in a small number of cases. 
A 65 year-old female presented with new onset, transient neurologic 
symptoms of ataxia, headaches, right-sided weakness, and dysarthria. A brain 
MRI demonstrated multiple enhancing supratentorial and infratentorial lesions 
with calvarium involvement. Right temporal lobe and dural masses were also 
noted and biopsied. Pathology described foamy histiocytes with tissue demonstrating a BRAFV600E 
mutation, which is consistent with ECD. Having predominantly progressive CNS and osseous involvement 
rendered the patient eligible for a phase II study of Vemurafenib therapy. She tolerated the treatment with 
clinical improvement over one year. She then presented with melena, was found to have a clean-based 
antral ulceration on EGD, and was treated conservatively. Several months later, a PET scan revealed a 
new subepithelial duodenal mass with FDG avidity. Patient underwent an endoscopic ultrasound guided 
fine needle aspiration (Figure 1). Pathology revealed a low grade neuroendocrine neoplasm and is 
currently pending endoscopic removal (Figure 2). References:
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Figure 1: 
A - Subepithelial lesion in the second portion of the duodenum adjacent to 
the papilla.
B - Lesion visualized with linear Echoendoscope showing a hypoechoic 
mass measuring 19.1 x 11.3 mm. It involves superficial layers 1 and 2, but 
spares the muscularis propria.
Figure 2: 
A - Nests of epithelial neoplasm (low power).
B - Nests of low grade tumor (high power) showing homogeneous population of cells.
C - Positive immunohistochemistry staining for Synaptophysin (a marker for neuroendocrine differentiation).
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BACKGROUND
CASE
The most recent multidisciplinary meta-analysis 
and literature review proposes that ECD can have a 
neuroendocrine predominance in addition to Osseous, 
CNS, Cardiac, Retroperitoneal, Orbital-craniofacial, and Pulmonary manifestations. Of 
the endocrinopathies described in literature, diabetes insipidus, hyperprolactinemia, 
gonadotropin insufficiency, and hypotestosteronism were most observed. The pituitary 
gland and stalk along with the hypothalamus have been known to display radiographic 
abnormalities with such findings. Gastrointestinal malignancies with neuroendocrine 
features are not typically associated with ECD and have not been noted to date. It is 
of great importance to keep in mind that the patient described here is one of the very 
few cases to receive “off-label” treatment with a Kinase inhibitor such as Vemurafenib. 
A common and well documented toxicity of this agent is cutaneous squamous cell 
carcinomas. BRAF inhibition is potentially unsafe with known risks of accelerating pre-
malignant lesions through compensatory overexpression of the proto-oncogene. With 
no clinical trials to assess the long-term effects of Vemurafenib, the critical question 
becomes whether or not the medication can be responsible for the development of 
neuroendocrine neoplasms. This case provides the opportunity to review and add to 
the current literature available on Erdheim-Chester disease while highlighting the 
importance of pursuing clinical trials to guide treatment.
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